Delgado-Leal L, Álvarez-Camarena B, De la Cruz-Valdivia JM, Hernández-Godínez E, Ramírez-Salazar A

Language: Spanish
References: 7
Page: 27-32
PDF size: 133.44 Kb.

ABSTRACT

«Statins» are drugs used to lower first-line serum cholesterol levels and cardiovascular prevention, both primary and secondary. Associated with myopathic syndromes ranging from myalgias statin myositis to rhabdomyolysis. The case of a woman 70 years of age with coronary artery disease trivascular, optimal treatment that included a picture of simvastatin and 7 days of evolution characterized by disorientation, myopathy and anuria, biochemical evidence of muscle damage, renal failure and elevation of hepatic transaminases, concluding rhabdomyolysis and acute hepatic and renal failure. Its evolution with treatment in place and development of fatal infectious complications. Review of the literature with definition of clinical variables that establish a risk profile for developing muscle complications from use of statin and the impact on identification and treatment.

REFERENCES

1. Grundy SM. Can statins cause chronic low-grade myopathy? Ann Intern Med 2002; 137: 617.

2. Grundy SM. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 1988; 319: 24.

3. Thompson PD, Clarkson PM, Rosenson RS, National Lipid Association Statin Safety Task Force Muscle Safety Expert Panel. An assessment of statin safety by muscle experts. Am J Cardiol 2006; 97: 69C.

4. Joy TR, Hegele RA. Narrative Review: Statin-Related Myopathy. Ann Intern Med 2009; 150: 858-868.

5. Kashani A, Phillips CO, Foody JM et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 2006; 114: 2788.

6. Hansen KE, Hildebrand JP, Ferguson EE, Stein JH. Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med 2005; 165: 2671.

7. Graham DJ, Staffa JA, Shatin D et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004; 292: 2585.